Billiontoone (NASDAQ:BLLN) Hits New 12-Month Low – Here’s Why

Shares of Billiontoone, Inc. (NASDAQ:BLLN) hit a new 52-week low during trading on Wednesday . The stock traded as low as $81.26 and last traded at $81.40, with a volume of 243156 shares traded. The stock had previously closed at $85.09.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of Billiontoone to a “hold” rating in a report on Saturday, November 15th. Wells Fargo & Company began coverage on Billiontoone in a report on Monday, December 1st. They issued an “equal weight” rating and a $110.00 target price on the stock. Piper Sandler reissued an “overweight” rating on shares of Billiontoone in a research report on Wednesday, December 10th. Jefferies Financial Group initiated coverage on Billiontoone in a report on Monday, December 1st. They issued a “hold” rating and a $117.00 price objective on the stock. Finally, Stifel Nicolaus initiated coverage on Billiontoone in a research note on Monday, December 1st. They issued a “buy” rating and a $145.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Billiontoone currently has a consensus rating of “Moderate Buy” and a consensus target price of $137.83.

Billiontoone Stock Down 3.8%

The firm has a market cap of $3.75 billion and a PE ratio of 818.40.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings results on Tuesday, December 9th. The company reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.06). The business had revenue of $83.52 million during the quarter, compared to analysts’ expectations of $82.86 million.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.